Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Sponsor: NGM Biopharmaceuticals, Inc
Summary
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Official title: A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
179
Start Date
2021-06-09
Completion Date
2025-07
Last Updated
2024-10-02
Healthy Volunteers
No
Conditions
Interventions
NGM707
Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
NGM707 plus pembrolizumab (KEYTRUDA®)
Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
NGM707 plus pembrolizumab (KEYTRUDA®)
Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
NGM707 plus pembrolizumab (KEYTRUDA®)
Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
NGM707 plus pembrolizumab (KEYTRUDA®)
Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
NGM707
Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
NGM707
Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
NGM707
Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Locations (27)
NGM Clinical Study Site
Los Angeles, California, United States
NGM Clinical Study Site
Newport Beach, California, United States
NGM Clinical Study Site
Santa Monica, California, United States
NGM Clinical Study Site
Santa Rosa, California, United States
NGM Clinical Study Site
Lone Tree, Colorado, United States
NGM Clinical Study Site
Washington D.C., District of Columbia, United States
NGM Clinical Study Site
Sarasota, Florida, United States
NGM Clinical Study Site
Baltimore, Maryland, United States
NGM Clinical Study Site
Boston, Massachusetts, United States
NGM Clinical Study Site
Grand Rapids, Michigan, United States
NGM Clinical Study Site
Omaha, Nebraska, United States
NGM Clinical Study Site
Albany, New York, United States
NGM Clinical Study Site
Greenville, South Carolina, United States
NGM Clinical Study Site
Dallas, Texas, United States
NGM Clinical Study Site
Dallas, Texas, United States
NGM Clinical Study Site
Houston, Texas, United States
NGM Clinical Study Site
San Antonio, Texas, United States
NGM Clinical Study Site
San Antonio, Texas, United States
NGM Clinical Study Site
Blacksburg, Virginia, United States
NGM Clinical Study Site
Vancouver, Washington, United States
NGM Clinical Study Site
Seoul, South Korea
NGM Clinical Study Site
Seoul, South Korea
NGM Clinical Study Site
Seoul, South Korea
NGM Clinical Study Site
New Taipei City, Taiwan
NGM Clinical Study Site
Taichung, Taiwan
NGM Clinical Study Site
Tainan, Taiwan
NGM Clinical Study Site
Taipei, Taiwan